Philadelphia, Pennsylvania – Phoenix Labs (“Phoenix”) has acquired a portfolio of well-established consumer health products from Sanofi Consumer Health (“Sanofi”). The portfolio includes Proctosedyl™, the leading pharmacy-only haemorrhoid treatment in Australia and a number of Essential Remedies found in many Australian homes. Additionally, the divestment package includes the Proctosedyl™ business in China, Malaysia, New Zealand, Singapore, Taiwan, Thailand and Ireland, and Anthisan® in New Zealand.
Plexus Ventures, a leading healthcare business development advisory firm established in 1990, assisted the Sanofi Consumer Health team with the divestment process leading to the closing of the transaction. “We are pleased to complete this divestment for Sanofi. We helped to generate intense competition for these assets demonstrating, once again, our capabilities in mature product divestments. This transaction allows Phoenix to reinforce its presence and commercial capabilities in Australia, New Zealand and South-East Asia,” commented Gabriele Tundo, Plexus Ventures’ Partner.
